Where Wealthy Investors Are Quietly Moving Their Money Next

Jan de Vries · 2026-10-12

Investment ambitions across the EU for AI and HealthTech are expansive — and the money is starting to follow. The EU's InvestAI initiative aims to mobilize €200 billion (roughly $217 billion) for artificial intelligence, including funding for major AI infrastructure. That's not pocket change. It's a signal about where the continent thinks the future is heading. The European Commission and the European Investment Bank Group have also launched BioTechEU to mobilize €10 billion (about $10.9 billion) for biotech and life sciences in 2026 and 2027. And this public push is happening alongside a quieter shift among wealthy private investors globally. Take the UBS Global Family Office Report 2026. It found that 65% of family offices were already invested in AI, and 33% were allocated to AI-enabled healthcare. Those are striking numbers for a group known for being cautious. So why is so much private capital moving toward AI and HealthTech? Let's dig in. ### The EU Is Putting Real Money Behind AI The scale of the EU's investment and infrastructure plans shows how strategically important AI has become. Infrastructure is one of the clearest examples. In July 2026, the EU requested up to seven AI Gigafactories, backed by up to €10 billion (about $10.9 billion) in EU and national funding. The expectation is that this unlocks at least €20 billion (around $21.7 billion) in additional private investment across the Union. Life sciences matter too. The sector already contributes nearly €1.5 trillion (about $1.63 trillion) in value and supports 29 million jobs across the EU. The EU is now trying to push that further through initiatives like BioTechEU, designed to mobilize €10 billion for biotechnology and life sciences investment during 2026 and 2027. The European Commission's wider life sciences strategy also includes measures to make multi-country clinical trials easier to fund. There's also €300 million (roughly $326 million) to stimulate procurement of life sciences innovations, including next-generation vaccines and affordable cancer solutions. ### AI and HealthTech Are Growing Fast for a Reason The EU has a massive life sciences industry, major research institutions, healthcare systems, and rapidly expanding AI infrastructure. That combination helps explain the investor interest. By April 2026, 19 AI Factories had been deployed across European supercomputers, supported by 13 regional AI Factory antennas. These give researchers, startups and businesses greater access to AI computing capacity. EU and participating EuroHPC countries have committed more than €2.6 billion (about $2.8 billion) to the AI Factories and Antennas initiative. Then there's the healthcare side. The European Health Data Space is designed to make health data easier to access and reuse securely across the EU for research, innovation and regulatory purposes. That creates potentially valuable infrastructure for medical research and AI development. Other EU projects include building specialist datasets: - Cancer Image Europe, expected to provide access to 60 million cancer images by the end of 2026 - The 1+ Million Genomes initiative, which aims to provide secure access to genomic and associated clinical data What's interesting is that the EU is also trying to move AI from research into clinical settings. In 2026, the European Commission made €9 million (about $9.8 million) available for two large-scale pilots of AI-powered medical imaging, covering X-rays, CT scans, MRI, PET and ultrasound. For investors, the attraction is clear: HealthTech is moving beyond laboratory research into real-world clinical testing and EU-backed deployment programs. ### A Big Capital Rotation Is Underway It's difficult to track exactly what every high-net-worth individual is investing in. Much private investment isn't publicly disclosed. But the family office data tells a story. When nearly two-thirds of family offices are already in AI, and a third have exposure to AI-enabled healthcare, you're not looking at a fringe trend. > "The smart money isn't chasing hype anymore. It's following the infrastructure, the data, and the regulatory tailwinds." That's essentially what's happening here. Public funding is de-risking early-stage infrastructure. Data initiatives are lowering research barriers. And clinical pilots are proving that AI can work in real medical settings, not just in labs. For investors watching from the sidelines, the message is worth considering: the EU is building the plumbing for AI and HealthTech on a massive scale. Private capital is starting to flow into that plumbing. Whether you're a family office, an angel investor, or just someone tracking where the next wave of growth might come from, this is a space worth watching closely. The numbers are big. The strategy is deliberate. And the rotation is already happening.